✦ LIBER ✦

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

✍ Scribed by Antoni Ribas, Jason A Chesney, Michael S Gordon, Amy P Abernethy, Theodore F Logan, David H Lawson, Bartosz Chmielowksi, John A Glaspy, Karl Lewis, Bo Huang, Erjian Wang, Poe-Hirr Hsyu, Jesus Gomez-Navarro, Diana Gerhardt, Margaret A Marshall, et al

Book ID: 119905287
Publisher: BioMed Central
Year: 2012
Tongue: English
Weight: 207 KB
Volume: 10
Category: Article
ISSN: 1479-5876
DOI: 10.1186/1479-5876-10-236

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

212 POSTER A Phase I study of huC242-DM4

212 POSTER A Phase I study of huC242-DM4 to assess the safety and pharmacokinetics of huC242-DM4 administered as a single intravenous infusion once every three weeks to subjects with solid tumors

✍ A.W. Tolcher; A. Ricart; J. Rodon; A. Patnaik; A. Mita; M. Mita; S. Sarantopolus 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 66 KB

27 ORAL Phase I dose escalation study of

27 ORAL Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 6-hour infusion on days 1, 8 and 15 every 4 weeks in patients with advanced/metastatic solid tumors

✍ M. De Jonge; N. Steeghs; J. Verweij; J.W.R. Nortier; F. Eskens; J. Ouwerkerk; C. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 82 KB

86 A phase I/II open-label study to asse

86 A phase I/II open-label study to assess the safety, pharmacokinetic profile, and preliminary antiviral effects of ost-577 (a human anti-hepatitis b surface antigen monoclonal antibody) administered to patients who are persistently hepatitis b antigen seropositive: DP Paar, MD, BM Montgomerie, RN, P Nadler, MD, ER Schiff, MD and RB Pollard, MD. The University of Texas Medical Branch at Galveston, Galveston, TX, USA; Protein Design Labs, Mountain View, CA, USA; the University of Miami, Miami, FL, USA

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 76 KB